| Abstrakt: |
A new study from Massachusetts General Hospital discusses the development of a tool called the Oral Oncolytic Nonadherence Estimator (ORACLE) that aims to predict nonadherence to oral cancer medications before treatment begins. The tool was created by a workgroup assembled through the National Community Oncology Dispensing Association and identifies six factors that impact compliance, including patient confidence, health literacy, perception of treatment, quality of life, social support, and complexity of chemotherapy regimen. The tool is designed to calculate a risk category for each patient and provide clinicians with strategies to manage nonadherence. The next steps for the tool include validation and piloting in clinical practice. [Extracted from the article] |
